McKesson Corporation (NYSE:MCK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 10, Deutsche ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

If you are wondering whether McKesson still looks attractive after its strong run, or whether much of the potential upside is ...

McKesson trades at $825.38 and has moved in lockstep with the market. Its shares have returned 14.5% over the last six months ...

Discover why McKesson (MCK) is a Buy: strong revenue, margin gains, and robust capital returns suggest 13.5% upside. Click here to read my most recent analysis.

McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2026 financial results after market close on Wednesday, February 4, 2026. The company will host a live webcast of the earnings ...

McKesson saw strong 2025 growth from GLP-1 tailwinds, but fading momentum, weak margins, and a 21x forward P/E show ...

Cencora, Inc. (NYSE: COR) is one of the stocks Jim Cramer recently discussed. During the lightning round, a caller inquired ...

McKesson Corporation's latest quarterly report presented a nuanced picture for investors. While the healthcare distribution giant comfortably surpassed earni ...

According to Mordor Intelligence, the healthcare IT market is valued at USD 413.14 billion in 2025, and is projected to surpass USD 839.67 billion by 2030, at a CAGR of 15.24% during the forecast ...